SEGMENT PERFORMANCE MEASURES AND EXPENSES (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES AND CONSOLIDATED NET LOSS

The table below provides a summary of the significant expense categories and consolidated net loss details provided to the CODM (in thousands):

	For the year ended December 31,
	(In thousands)						Change Increase (Decrease)
	2024			2023
Operating Expenses:
Clinical Research
OVATION	$	1,386		$	1,197		$	189		15.8	%
Vaccine		1,420			-			1,420		100.0	%
Other clinical and regulatory		2,434			1,793			641		35.8	%
Subtotal		5,240			2,990			2,250		75.3	%
Non-Clinical R&D and CMC
OVATION		1,819			1,504			315		20.9	%
PlaCCine Vaccine		2,554			4,511			(1,957	)	(43.4	)%
Manufacturing (CMC)		2,026			2,283			(257	)	(11.3	)%
Subtotal		6,399			8,298			(1,899	)	(22.9	)%
Research and development expenses		11,639			11,288			351		3.1	%
General and administrative expenses		7,493			9,742			(2,249	)	(23.1	)%
Total operating expenses		19,132			21,030			(1,898	)	(9.0	)%
Loss from operations	$	(19,132	)	$	(21,030	)	$	(1,898	)	(9.0	)%